TABLE 1.
ANS regulates intestinal cell proliferation.
| Populations | Conditions | Autonomic nerve receptors | Functions | References |
| Intestinal epithelial cells (IECs) | M1KO-M5KO | Knockout M1-5 muscarinic receptors | Increase depth of ileal crypts, increase proliferation | Greig and Cowles (2017) |
| Cholinergic agonist carbachol | Activate mAChR | Reduce proliferation | Takahashi et al. (2014) | |
| CaCo2 cell transfected with α2A epinephrine receptor | Activate α2A adrenergic receptor | Increase proliferation | Schaak et al. (2000) | |
| α2 adrenergic agonist clonidine | Activate α2 adrenergic receptor | Increase proliferation | Kennedy et al. (1983) | |
| α adrenergic antagonist phentolamine | Inhibit α adrenergic receptor | Reduce proliferation | Kennedy et al. (1983) | |
| α1 adrenergic agonist phenylephrine β adrenergic agonist isoprenaline | Inhibit α-1 and β adrenergic receptors | Inhibit proliferation | Kennedy et al. (1983) | |
| NE and ACH treatment | Activate adrenergic receptor | Reduce the expression of the cyclin D1 | Davis et al. (2018) | |
| Intestinal stem cells (ISCs) | Mouse small intestine | M1,3 muscarinic receptors | Specifically increase in ISCs relative to villus cells or Paneth cells | Davis et al. (2018) |
| Rat small intestine | M3,5 muscarinic receptors | Expression in ISCs | Lundgren et al. (2011) | |
| Mouse small intestine | α2A adrenergic receptor | Specifically increase in ISCs relative to villus cells or Paneth cells | Davis et al. (2018) | |
| ISO treatment after chemotherapy | Activate β2 adrenergic receptor | Ameliorate the reduction in ISCs during chemotherapy | Zeng et al. (2020) |